سوق الآزاسيتيدين العالمي - اتجاهات الصناعة والتوقعات حتى عام 2032

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL AZACITIDINE MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL AZACITIDINE MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL AZACITIDINE MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 MERGERS AND ACQUISITIONS

10.8 FUTURE OUTLOOK

11 EPIDEMIOLOGY

11.1 INCIDENCE OF ALL BY GENDER

11.2 TREATMENT RATE

11.3 MORTALITY RATE

11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

11.5 PATIENT TREATMENT SUCCESS RATES

12 REGULATORY COMPLIANCE

12.1 REGULATORY AUTHORITIES

12.2 REGULATORY CLASSIFICATIONS

12.2.1 CLASS I

12.2.2 CLASS II

12.2.3 CLASS III

12.3 REGULATORY SUBMISSIONS

12.4 INTERNATIONAL HARMONIZATION

12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

12.6 REGULATORY CHALLENGES AND STRATEGIES

13 PIPELINE ANALYSIS

13.1 CLINICAL TRIALS AND PHASE ANALYSIS

13.2 DRUG THERAPY PIPELINE

13.3 PHASE III CANDIDATES

13.4 PHASE II CANDIDATES

13.5 PHASE I CANDIDATES

13.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR AZACITIDINE MARKET

Company Name Product Name

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR AZACITIDINE MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved but Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR AZACITIDINE MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR AZACITIDINE MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR AZACITIDINE MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

14 REIMBURSEMENT FRAMEWORK

15 OPPUTUNITY MAP ANALYSIS

16 VALUE CHAIN ANALYSIS

17 HEALTHCARE ECONOMY

17.1 HEALTHCARE EXPENDITURE

17.2 CAPITAL EXPENDITURE

17.3 CAPEX TRENDS

17.4 CAPEX ALLOCATION

17.5 FUNDING SOURCES

17.6 INDUSTRY BENCHMARKS

17.7 GDP RATION IN OVERALL GDP

17.8 HEALTHCARE SYSTEM STRUCTURE

17.9 GOVERNMENT POLICIES

18 GLOBAL AZACITIDINE MARKET, BY TYPES

18.1 OVERVIEW

18.2 0.995

18.3 <99.5%

18.4 OTHERS

19 GLOBAL AZACITIDINE MARKET, BY DOSAGE

19.1 OVERVIEW

19.2 STANDARD SYRINGES

19.3 PRE-FILLED SYRINGES

20 GLOBAL AZACITIDINE MARKET, BY STRENGTH

20.1 OVERVIEW

20.2 TABLET

20.2.1 200MG

20.2.2 300MG

20.2.3 OTHERS

20.3 INJECTION

20.3.1 25 MG/ML POWDER FOR INJECTION

20.3.2 100MG/SINGLE-DOSE VIAL INJECTION

20.3.3 OTHERS

21 GLOBAL AZACITIDINE MARKET, BY ROUTE OF ADMINISTRATION

21.1 OVERVIEW

21.2 ORAL

21.2.1 TABLETS

21.2.2 OTHERS

21.3 PARENTERAL

21.3.1 INTRAVENEOUS

21.3.2 SUBCUTANEOUS

21.3.3 OTHERS

21.4 OTHERS

22 GLOBAL AZACITIDINE MARKET, BY DRUG TYPE

22.1 OVERVIEW

22.2 BRANDED

22.2.1 VIDAZA

22.2.2 ONUREG

22.2.3 OTHERS

22.3 GENERICS

23 GLOBAL AZACITIDINE MARKET, BY AGE GROUP

23.1 OVERVIEW

23.2 PEDIATRIC

23.3 ADULT

23.4 GERIATRIC

24 GLOBAL AZACITIDINE MARKET, BY GEDNER

24.1 OVERVIEW

24.2 MALE

24.2.1 PEDIATRIC

24.2.2 ADULT

24.2.3 GERIATRIC

24.3 FEMALE

24.3.1 PEDIATRIC

24.3.2 ADULT

24.3.3 GERIATRIC

25 GLOBAL AZACITIDINE MARKET, BY APPLICATION

25.1 OVERVIEW

25.2 REFRACTORY ANEMIA (RA)

25.3 REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB)

25.4 MYELODYSPLASTIC SYNDROMES

25.5 CHRONIC MYELOMONOCYTIC LEUKEMIA (CMMOL)

25.6 ACUTE MYELOID LEUKEMIA

25.7 OTHERS

26 GLOBAL AZACITIDINE MARKET, BY END USER

26.1 OVERVIEW

26.2 HOSPITALS

26.2.1 BY TYPE

26.2.1.1. PUBLIC

26.2.1.2. PRIVATE

26.2.2 BY LEVEL

26.2.2.1. TIER 1

26.2.2.2. TIER 2

26.2.2.3. TIER 3

26.3 SPECIALTY CLINICS

26.3.1 PUBLIC

26.3.2 PRIVATE

26.4 ONCOLOGY CENTRES

26.5 HOME HEALTHCARE

26.6 ACADEMIC AND RESEARCH INSTITUTION

26.7 OTHERS

27 GLOBAL AZACITIDINE MARKET, BY DISTRIBUTION CHANNEL

27.1 OVERVIEW

27.2 DIRECT TENDER

27.3 RETAIL SALES

27.3.1 ONLINE

27.3.1.1. COMPANY WEBSITE

27.3.1.2. E-DRUG STORES

27.3.1.3. OTHERS

27.3.2 OFFLINE

27.3.2.1. HOSPITAL PHARMACY

27.3.2.2. MEDICINE STORES

27.3.2.3. OTHERS

27.4 OTHERS

28 GLOBAL AZACITIDINE MARKET, COMPANY LANDSCAPE

28.1 COMPANY SHARE ANALYSIS: GLOBAL

28.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

28.3 COMPANY SHARE ANALYSIS: EUROPE

28.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

28.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

28.6 COMPANY SHARE ANALYSIS: SOUTH AMERICA

28.7 MERGERS & ACQUISITIONS

28.8 NEW PRODUCT DEVELOPMENT & APPROVALS

28.9 EXPANSIONS

28.1 REGULATORY CHANGES

28.11 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

29 GLOBAL AZACITIDINE MARKET, BY REGION

29.1 GLOBAL AZACITIDINE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

29.1.1 NORTH AMERICA

29.1.1.1. U.S.

29.1.1.2. CANADA

29.1.1.3. MEXICO

29.1.2 EUROPE

29.1.2.1. GERMANY

29.1.2.2. FRANCE

29.1.2.3. U.K.

29.1.2.4. ITALY

29.1.2.5. SPAIN

29.1.2.6. RUSSIA

29.1.2.7. TURKEY

29.1.2.8. BELGIUM

29.1.2.9. NETHERLANDS

29.1.2.10. HUNGARY

29.1.2.11. LITHUANIA

29.1.2.12. AUSTRIA

29.1.2.13. IRELAND

29.1.2.14. NORWAY

29.1.2.15. POLAND

29.1.2.16. SWITZERLAND

29.1.2.17. REST OF EUROPE

29.1.3 ASIA-PACIFIC

29.1.3.1. JAPAN

29.1.3.2. CHINA

29.1.3.3. SOUTH KOREA

29.1.3.4. INDIA

29.1.3.5. AUSTRALIA

29.1.3.6. SINGAPORE

29.1.3.7. THAILAND

29.1.3.8. MALAYSIA

29.1.3.9. INDONESIA

29.1.3.10. VIETNAM

29.1.3.11. PHILIPPINES

29.1.3.12. REST OF ASIA-PACIFIC

29.1.4 SOUTH AMERICA

29.1.4.1. BRAZIL

29.1.4.2. ARGENTINA

29.1.4.3. PERU

29.1.4.4. REST OF SOUTH AMERICA

29.1.5 MIDDLE EAST AND AFRICA

29.1.5.1. SOUTH AFRICA

29.1.5.2. SAUDI ARABIA

29.1.5.3. UAE

29.1.5.4. EGYPT

29.1.5.5. KUWAIT

29.1.5.6. ISRAEL

29.1.5.7. REST OF MIDDLE EAST AND AFRICA

29.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

30 GLOBAL AZACITIDINE MARKET, SWOT AND DBMR ANALYSIS

31 GLOBAL AZACITIDINE MARKET, COMPANY PROFILE

31.1 VBSHILPA

31.1.1 COMPANY OVERVIEW

31.1.2 REVENUE ANALYSIS

31.1.3 GEOGRAPHIC PRESENCE

31.1.4 PRODUCT PORTFOLIO

31.1.5 RECENT DEVELOPEMENTS

31.2 BRISTOL-MYERS SQUIBB COMPANY

31.2.1 COMPANY OVERVIEW

31.2.2 REVENUE ANALYSIS

31.2.3 GEOGRAPHIC PRESENCE

31.2.4 PRODUCT PORTFOLIO

31.2.5 RECENT DEVELOPEMENTS

31.3 HIKMA PHARMACEUTICALS PLC

31.3.1 COMPANY OVERVIEW

31.3.2 REVENUE ANALYSIS

31.3.3 GEOGRAPHIC PRESENCE

31.3.4 PRODUCT PORTFOLIO

31.3.5 RECENT DEVELOPEMENTS

31.4 INTAS PHARMACEUTICALS LIMITED

31.4.1 COMPANY OVERVIEW

31.4.2 REVENUE ANALYSIS

31.4.3 GEOGRAPHIC PRESENCE

31.4.4 PRODUCT PORTFOLIO

31.4.5 RECENT DEVELOPEMENTS

31.5 ACCORD HEALTHCARE

31.5.1 COMPANY OVERVIEW

31.5.2 REVENUE ANALYSIS

31.5.3 GEOGRAPHIC PRESENCE

31.5.4 PRODUCT PORTFOLIO

31.5.5 RECENT DEVELOPEMENTS

31.6 ACTAVIS LLC

31.6.1 COMPANY OVERVIEW

31.6.2 REVENUE ANALYSIS

31.6.3 GEOGRAPHIC PRESENCE

31.6.4 PRODUCT PORTFOLIO

31.6.5 RECENT DEVELOPEMENTS

31.7 AMNEAL PHARMACEUTICALS LLC.

31.7.1 COMPANY OVERVIEW

31.7.2 REVENUE ANALYSIS

31.7.3 GEOGRAPHIC PRESENCE

31.7.4 PRODUCT PORTFOLIO

31.7.5 RECENT DEVELOPEMENTS

31.8 CIPLA

31.8.1 COMPANY OVERVIEW

31.8.2 REVENUE ANALYSIS

31.8.3 GEOGRAPHIC PRESENCE

31.8.4 PRODUCT PORTFOLIO

31.8.5 RECENT DEVELOPEMENTS

31.9 DR. REDDY’S LABORATORIES LIMITED

31.9.1 COMPANY OVERVIEW

31.9.2 REVENUE ANALYSIS

31.9.3 GEOGRAPHIC PRESENCE

31.9.4 PRODUCT PORTFOLIO

31.9.5 RECENT DEVELOPEMENTS

31.1 EUGIA US LLC

31.10.1 COMPANY OVERVIEW

31.10.2 REVENUE ANALYSIS

31.10.3 GEOGRAPHIC PRESENCE

31.10.4 PRODUCT PORTFOLIO

31.10.5 RECENT DEVELOPEMENTS

31.11 EUROHLTH INTL SARL

31.11.1 COMPANY OVERVIEW

31.11.2 REVENUE ANALYSIS

31.11.3 GEOGRAPHIC PRESENCE

31.11.4 PRODUCT PORTFOLIO

31.11.5 RECENT DEVELOPEMENTS

31.12 JIANGSU HANSOH PHARM

31.12.1 COMPANY OVERVIEW

31.12.2 REVENUE ANALYSIS

31.12.3 GEOGRAPHIC PRESENCE

31.12.4 PRODUCT PORTFOLIO

31.12.5 RECENT DEVELOPEMENTS

31.13 MEITHEAL

31.13.1 COMPANY OVERVIEW

31.13.2 REVENUE ANALYSIS

31.13.3 GEOGRAPHIC PRESENCE

31.13.4 PRODUCT PORTFOLIO

31.13.5 RECENT DEVELOPEMENTS

31.14 MSN LABS PVT LTD

31.14.1 COMPANY OVERVIEW

31.14.2 REVENUE ANALYSIS

31.14.3 GEOGRAPHIC PRESENCE

31.14.4 PRODUCT PORTFOLIO

31.14.5 RECENT DEVELOPEMENTS

31.15 NATCO PHARMA LTD

31.15.1 COMPANY OVERVIEW

31.15.2 REVENUE ANALYSIS

31.15.3 GEOGRAPHIC PRESENCE

31.15.4 PRODUCT PORTFOLIO

31.15.5 RECENT DEVELOPEMENTS

31.16 FLORENCIA HEALTHCARE

31.16.1 COMPANY OVERVIEW

31.16.2 REVENUE ANALYSIS

31.16.3 GEOGRAPHIC PRESENCE

31.16.4 PRODUCT PORTFOLIO

31.16.5 RECENT DEVELOPEMENTS

31.17 GETWELL PHARMA

31.17.1 COMPANY OVERVIEW

31.17.2 REVENUE ANALYSIS

31.17.3 GEOGRAPHIC PRESENCE

31.17.4 PRODUCT PORTFOLIO

31.17.5 RECENT DEVELOPEMENTS

31.18 TAJ PHARMA GROUP

31.18.1 COMPANY OVERVIEW

31.18.2 REVENUE ANALYSIS

31.18.3 GEOGRAPHIC PRESENCE

31.18.4 PRODUCT PORTFOLIO

31.18.5 RECENT DEVELOPEMENTS

31.19 HETERO HEALTHCARE LIMITED

31.19.1 COMPANY OVERVIEW

31.19.2 REVENUE ANALYSIS

31.19.3 GEOGRAPHIC PRESENCE

31.19.4 PRODUCT PORTFOLIO

31.19.5 RECENT DEVELOPEMENTS

31.2 ABBOTT

31.20.1 COMPANY OVERVIEW

31.20.2 REVENUE ANALYSIS

31.20.3 GEOGRAPHIC PRESENCE

31.20.4 PRODUCT PORTFOLIO

31.20.5 RECENT DEVELOPEMENTS

31.21 APIS LABOR GMBH (MARKETING AUTH.- MYLAN IRELAND LIMITED )

31.21.1 COMPANY OVERVIEW

31.21.2 REVENUE ANALYSIS

31.21.3 GEOGRAPHIC PRESENCE

31.21.4 PRODUCT PORTFOLIO

31.21.5 RECENT DEVELOPEMENTS

31.22 BRECKENRIDGE PHARMACEUTICAL, INC.

31.22.1 COMPANY OVERVIEW

31.22.2 REVENUE ANALYSIS

31.22.3 GEOGRAPHIC PRESENCE

31.22.4 PRODUCT PORTFOLIO

31.22.5 RECENT DEVELOPEMENTS

31.23 ARMAS PHARMACEUTICALS, INC.

31.23.1 COMPANY OVERVIEW

31.23.2 REVENUE ANALYSIS

31.23.3 GEOGRAPHIC PRESENCE

31.23.4 PRODUCT PORTFOLIO

31.23.5 RECENT DEVELOPEMENTS

*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

32 RELATED REPORTS

33 CONCLUSION

34 QUESTIONNAIRE

35 ABOUT DATA BRIDGE MARKET RESEARCH